Evidence map›Paper›PMID 35643952›Full record

Trial reportAnnals of hematology2022

Sequential eradication of Helicobacter pylori as a treatment for immune thrombocytopenia in patients with moderate thrombocytopenia: a multicenter prospective randomized phase 3 study.

Boram Han, Hyo Jung Kim, Ho-Young Yhim, Doyeun Oh, Sung Hwa Bae, Ho-Jin Shin, Won-Sik Lee, JiHyun Kwon, Jeong-Ok Lee, Hwa Jung Kim and 1 more

Abstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Annals of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Impact ofDiagnostics (Basel, Switzerland) · 2023
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Boram Han *Division of Hematology-Oncology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea.
Hyo Jung Kim *Division of Hematology-Oncology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea.
Ho-Young YhimDivision of Hematology-Oncology, Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Republic of Korea.
Doyeun OhDivision of Hematology-Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
Sung Hwa BaeDivision of Hematology-Oncology, Department of Internal Medicine, Daegu Catholic University Hospital, Daegu, Republic of Korea.
Ho-Jin ShinDivision of Hematology-Oncology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea.
Won-Sik LeeDivision of Hematology-Oncology, Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Republic of Korea.
JiHyun KwonDivision of Hematology-Oncology, Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
Jeong-Ok LeeDivision of Hemato-Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
Hwa Jung KimDepartment of Prevention Medicine, University of Ulsan College of Medicine, Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, Seoul, Republic of Korea.
Soo-Mee BangDivision of Hemato-Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea. smbang7@snu.ac.kr.
Asan Medical Center · KRSeoul National University Bundang Hospital · KRCHA University Bundang Medical Center · KRChungbuk National University · KRHallym University Sacred Heart Hospital · KRInje University Busan Paik Hospital · KRJeonbuk National University · KRPusan National University Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to several issues, standard treatments are not recommended for asymptomatic patients with moderate immune thrombocytopenia (ITP). Since platelet responses are reported in some patients with Helicobacter pylori (H. pylori)-positive ITP after eradication, we conducted a multicenter, phase 3 study to evaluate the safety and efficacy of recently established sequential eradication for these patients having moderate thrombocytopenia. Persistent or chronic ITP patients with platelet count (30 × 10

Indexed as

AnemiaHelicobacter InfectionsHelicobacter pyloriPurpura, Thrombocytopenic, IdiopathicThrombocytopeniaAnti-Bacterial AgentsHumansProspective StudiesAnti-Bacterial AgentsEradicationHelicobacter pyloriImmune thrombocytopeniaThrombocytopenia

Identifiers

PMID35643952
OpenAlexW4281746014

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.